Clinical Trial Update: Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and dose ranging of a Human Insulin Receptor MAb-IDUA fusion protein in adults and children with Mucopolysaccharidosis I comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis

Drugs mentioned

• Human Insulin Receptor MAb-IDUA fusion protein (insulin receptor monoclonal antibody-IDUA fusion protein)

Snippet

Sponsor: ArmaGen, Inc | Conditions: Mucopolysaccharidosis I | Phase 1, Phase 2 | Status: COMPLETED